Arketamine for bipolar depression: Open-label, dose-escalation, pilot study
Igor D. Bandeira, Gustavo C. Leal, Fernanda S. Correia‐Melo, Breno Souza‐Marques, Samantha S. Silva, Daniel H. Lins-Silva, Rodrigo P. Mello, Flávia Vieira, Igor D. Bandeira, Daniela Faria-Guimarães, Beatriz Carneiro, Ana Teresa Caliman‐Fontes, Flávio Kapczinski, Ângela Miranda‐Scippa, Acioly L.T. Lacerda, Lucas C. Quarantini
Topics & Concepts
Bipolar disorderDepression (economics)Rating scaleMajor depressive disorderAntidepressantPsychologyBipolar II disorderMajor depressive episodeHamilton Rating Scale for DepressionKetamineTreatment-resistant depressionMedicineInternal medicinePsychiatryMoodEconomicsAnxietyDevelopmental psychologyMacroeconomicsTreatment of Major DepressionBipolar Disorder and TreatmentTryptophan and brain disorders